PHASE 1 TRIAL OF HSVTK GENE THERAPY FOR CNS TUMORS

HSVTK 基因治疗 CNS 肿瘤的一期试验

• 批准号: 6113254
• 负责人: JANE B ALAVI
• 金额: $ 2.51万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6113254
• 关键词: Adenoviridae; Alphaherpesvirinae; brain neoplasms; central nervous system neoplasms; clinical research; clinical trial phase I; drug delivery systems; ganciclovir; gene therapy; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer therapy; outcomes research; recombinant virus; thymidine kinase; transfection /expression vector

The purpose of this study is to determine the effectiveness and safety of a recombinant (laboratory-produced) adenovirus injected into brain tumors. The virus has been expecially designed to carry a gene called herpes simplex thymidine kinase (HSV-TK). The study will investigate whether this gene (a gene is part 0of the nucleus of a cell) will enter brain tumor cells and make them sensitive to the killing effect of the drug ganciclovir.

本研究的目的是确定重组（实验室生产）腺病毒注射到脑肿瘤中的有效性和安全性。这种病毒被特别设计成携带一种称为单纯疱疹胸苷激酶（HSV-TK）的基因。 这项研究将调查这种基因（基因是细胞核的一部分）是否会进入脑肿瘤细胞，使它们对药物更昔洛韦的杀伤作用敏感。